TherapeuticsMD, Inc.TXMDNASDAQ
Loading
Year-over-year research & development expense growth
Latest
0.00%
↑ 100% vs avg
Percentile
P54
Within normal range
Average
-14.17%
Historical baseline
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | 0.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | 100.00% |
| Q4 2022 | -467.99% |
| Q3 2022 | -29.62% |
| Q2 2022 | 12.86% |
| Q1 2022 | -1.41% |
| Q4 2021 | -11.53% |
| Q3 2021 | -20.19% |
| Q2 2021 | -1.90% |
| Q1 2021 | -14.37% |
| Q4 2020 | 18.11% |
| Q3 2020 | -26.08% |
| Q2 2020 | -16.12% |
| Q1 2020 | -26.24% |
| Q4 2019 | 8.69% |
| Q3 2019 | -17.86% |
| Q2 2019 | -21.42% |
| Q1 2019 | -6.45% |
| Q4 2018 | 0.67% |
| Q3 2018 | -1.33% |
| Q2 2018 | -3.42% |
| Q1 2018 | -35.86% |
| Q4 2017 | 70.50% |
| Q3 2017 | -26.15% |
| Q2 2017 | 12.84% |
| Q1 2017 | -25.30% |
| Q4 2016 | -29.48% |
| Q3 2016 | 5.95% |
| Q2 2016 | -8.32% |
| Q1 2016 | 13.91% |
| Q4 2015 | -19.29% |